Smith & Nephew Inc. Expands Presence At The Symposium On Advanced Wound Care

FORT WORTH, Texas, Sept. 25, 2015 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announced today that several company-sponsored posters and symposia will be presented at the 2015 Fall Symposium on Advanced Wound Care (SAWC) Annual Meeting which begins this Saturday, September 26 in Las Vegas, Nevada.

"Smith & Nephew has supported healthcare professionals for over 150 years, with an evidence-based portfolio of products to address wound care prevention and treatment goals," said Glenn Warner, president of Smith & Nephew's Advanced Wound Management Division. "We are dedicated to presenting our research at symposia such as the Symposium on Advanced Wound Care to further our understanding of the tremendous burden of chronic wounds, which is estimated at $33 billion per year in the U.S."

The following Smith & Nephew-sponsored data will be presented via poster presentation at the 2015 SAWC Annual Meeting on Sunday, September 27 from 8:00 AM 4:00 PM PDT:

• (#IR-007) Finding the Sweet Spot for Treating Pressure Ulcers with Clostridial Collagenase Ointment: Results from the U.S. Wound Registry
• (#IR-009) Comparative Effectiveness of Cadexomer Iodine to a Hydrofiber Silver Dressing for Treatment of Venous Leg Ulcers in Outpatient Care Settings
• (#IR-010) Comparative Effectiveness of Cadexomer Iodine to Antibacterial Honey for Treatment of Venous Leg Ulcers in Outpatient Care Settings
• (#IR-011) Comparative Effectiveness of Clostridial Collagenase Ointment for the Treatment of Venous Leg Ulcers in Outpatient Care Settings
• (#IR-012) Comparative Effectiveness of Clostridial Collagenase Ointment to Antibacterial Honey for Treatment of Venous Leg Ulcers in Outpatient Care Settings
• (#IR-013) Comparative Effectiveness of Two Silver Dressings for Treatment of Venous Leg Ulcers in Outpatient Care Settings

In addition, the following company-sponsored symposia (non-accredited) will be offered in conjunction with the 2015 SAWC annual meeting:

• Symposium: The Role of Debridement in Wound Bed Preparation; Sunday, September 27, 2015; 6:30 P.M. 8:00 P.M. PDT; registration required
• Symposium: Diabetic Neuropathic Ulcers Recognizing the Significant Burden and Reviewing a Treatment Option; Saturday, September 26; 12:10 1:40 PM PDT; registration required

About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to supporting healthcare professionals in their daily efforts to improve the lives of their patients. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 14,000 employees and a presence in more than 100 countries. Annual sales in 2014 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

Media Inquiries:
Christie Teller
817-905-7158
christie.teller@smith-nephew.com

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/smith--nephew-expands-presence-at-the-symposium-on-advanced-wound-care-300149069.html

SOURCE Smith & Nephew